Clinical Interpretation of Urine Drug Tests: What Clinicians Need to Know About Urine Drug Screens

Mayo Clinic Proceedings

Volumn 92, Issue 5, 2017, Pages 774-796

  Moeller, Karen E ^a   Kissack, Julie C ^b   Atayee, Rabia S ^c   Lee, Kelly C ^c  

^a UNIVERSITY OF KANSAS   (United States)

^b HARDING UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABINOID; CENTRAL DEPRESSANT AGENT; CENTRAL STIMULANT AGENT; DESIGNER DRUG; HERBACEOUS AGENT; PSYCHEDELIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; STREET DRUG;

DRUG ABUSE; DRUG DEPENDENCE; DRUG SCREENING; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; INTERPRETATION BIAS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MASS FRAGMENTOGRAPHY; MEDICAL DECISION MAKING; PHYSICIAN; REVIEW; URINALYSIS; URINE DRUG TEST; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; SUBSTANCE-RELATED DISORDERS; URINE;

FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; URINALYSIS;

EID: 85015668925     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2016.12.007     Document Type: Review

References (226)

1. 1 Substance Abuse and Mental Health Services Administration, Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. 2015, Substance Abuse and Mental Health Services Administration, Rockville, MD HHS Publication (SMA) 15-4927 http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf Accessed October 16, 2016.
2. 2 Reisfield, G.M., Webb, F.J., Bertholf, R.L., Sloan, P.A., Wilson, G.R., Family physicians’ proficiency in urine drug test interpretation. J Opioid Manag 3:6 (2007), 333–337.
3. 3 Reisfield, G.M., Bertholf, R., Barkin, R.L., Webb, F., Wilson, G., Urine drug test interpretation: what do physicians know?. J Opioid Manag 3:2 (2007), 80–86.
4. 4 Substance Abuse and Mental Health Services Administration, Clinical Drug Testing in Primary Care. 2012, Substance Abuse and Mental Health Services Administration, Rockville, MD HHS Publication (SMA) 12-4668 https://store.samhsa.gov/shin/content/SMA12-4668/SMA12-4668.pdf Accessed October 12, 2016.
5. 5 Armbruster, D.A., Schwarzhoff, R.H., Hubster, E.C., Liserio, M.K., Enzyme immunoassay, kinetic microparticle immunoassay, radioimmunoassay, and fluorescence polarization immunoassay compared for drugs-of-abuse screening. Clin Chem 39:10 (1993), 2137–2146.
6. 6 Nichols, J.H., Christenson, R.H., Clarke, W., et al., National Academy of Clinical Biochemistry. Executive summary. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline: evidence-based practice for point-of-care testing. Clin Chim Acta 379:1-2 (2007), 14–28 discussion 29-30.
7. 7 Mandatory guidelines for federal workplace drug testing programs. Fed Regist 73:228 (2008), 71858–71907.
8. 8 Luzzi, V.I., Saunders, A.N., Koenig, J.W., et al. Analytic performance of immunoassays for drugs of abuse below established cutoff values. Clin Chem 50:4 (2004), 717–722.
9. 9 Council on Scientific Affairs, Scientific issues in drug testing. JAMA 257:22 (1987), 3110–3114.
10. 10 Heit, H.A., Gourlay, D.L., Urine drug testing in pain medicine. J Pain Symptom Manage 27:3 (2004), 260–267.
11. 11 Inaba, D.S., Cohen, W.E., Uppers, Downers, All Arounders. Physical and Mental Effects of Psychoactive Drugs. 8th ed., 2014, CNS Publications, Inc, Medford, OR.
12. 12 Moeller, K.E., Lee, K.C., Kissack, J.C., Urine drug screening: practical guide for clinicians. Mayo Clin Proc 83:1 (2008), 66–76.
13. 13 NMS Labs Synthetic Cannabinoids ELISA FAQ. NMS Labs website. http://www.nmslabs.com/services-forensic-K2-ELISA-FAQ Accessed July 26, 2016.
14. 14 Rosse, R.B., Deutsch, L.H., Deutsch, S.I., Medical assessment and laboratory testing in psychiatry., 7th ed Sadock, B.I., Sadock, V.A., (eds.) Kaplan and Sadock's Comprehensive Textbook of Psychiatry, Vol 1, 2000, Lippincott Williams &Wilkins, Philadelphia, PA, 732–755.
15. 15 Synthetic cannabinoid testing–urine. Frequently asked questions. Redwood Toxicology Laboratory website. https://www.redwoodtoxicology.com/docs/services/3370_sc_faq.pdf Accessed July 26, 2016.
16. 16 Verstraete, A.G., Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit 26:2 (2004), 200–205.
17. 17 Woelfel, J.A., Drug abuse urine tests: false-positive results. Pharmacist Lett/Prescribers Lett, 21(3), 2005, 210314.
18. 18 Casavant, M.J., Urine drug screening in adolescents. Pediatr Clin North Am 49:2 (2002), 317–327.
19. 19 Hammett-Stabler, C.A., Pesce, A.J., Cannon, D.J., Urine drug screening in the medical setting. Clin Chim Acta 315:1-2 (2002), 125–135.
20. 20 Warner, A., Interference of common household chemicals in immunoassay methods for drugs of abuse. Clin Chem 35:4 (1989), 648–651.
21. 21 Jaffee, W.B., Trucco, E., Levy, S., Weiss, R.D., Is this urine really negative? A systematic review of tampering methods in urine drug screening and testing. J Subst Abuse Treat 33:1 (2007), 33–42.
22. 22 Dasgupta, A., The effects of adulterants and selected ingested compounds on drugs-of-abuse testing in urine. Am J Clin Pathol 128:3 (2007), 491–503.
23. 23 Langman LJ, Jannetto PJ, eds. Laboratory Medicine Practice Guidelines. Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients. Washington, DC: American Association for Clinical Chemistry, The National Academy of Clinical Biochemistry. https://www.aacc.org/∼/media/practice-guidelines/pain-management/rough-draft-pain-management-lmpg-v6aacc.pdf?la=en. Accessed October 16, 2016.
24. 24 Hawks, R.l., Chaign, C.N., (eds.) Urine Testing for Drugs of Abuse, 1986, Department of Health and Human Services, National Institute on Drug Abuse, Rockville, MD NIDA Research Monograph 73 http://archives.drugabuse.gov/pdf/monographs/download73.html Accessed October 12, 2016.
25. 25 Cody, J.T., Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. J Occup Environ Med 44:5 (2002), 435–450.
26. 26 Colbert, D.L., Possible explanation for trimethobenzamide cross-reaction in immunoassays of amphetamine/methamphetamine. Clin Chem 40:6 (1994), 948–949.
27. 27 Fenderson, J.L., Stratton, A.N., Domingo, J.S., Matthews, G.O., Tan, C.D., Amphetamine positive urine toxicology screen secondary to atomoxetine. Case Rep Psychiatry, 2013, 2013, 381261.
28. 28 Fucci, N., False positive results for amphetamine in urine of a patient with diabetes mellitus. Forensic Sci Int, 223(1-3), 2012, e60.
29. 29 Gilbert, R.B., Peng, P.I., Wong, D., A labetalol metabolite with analytical characteristics resembling amphetamines. J Anal Toxicol 19:2 (1995), 84–86.
30. 30 Grinstead, G.F., Ranitidine and high concentrations of phenylpropanolamine cross react in the EMIT monoclonal amphetamine/methamphetamine assay. Clin Chem 35:9 (1989), 1998–1999.
31. 31 Jones, R., Klette, K., Kuhlman, J.J., et al. Trimethobenzamide cross-reacts in immunoassays of amphetamine/methamphetamine. Clin Chem 39:4 (1993), 699–700.
32. 32 Kaplan, J., Shah, P., Faley, B., Siegel, M.E., Case reports of aripiprazole causing false-positive urine amphetamine drug screens in children. Pediatrics 136:6 (2015), e1625–e1628.
33. 33 Kelly, K.L., Ranitidine cross-reactivity in the EMIT d.a.u. Monoclonal Amphetamine/Methamphetamine Assay. Clin Chem 36:7 (1990), 1391–1392.
34. 34 Levine, B.S., Caplan, Y.H., Isometheptene cross reacts in the EMIT amphetamine assay. Clin Chem 33:7 (1987), 1264–1265.
35. 35 Liu, L., Wheeler, S.E., Rymer, J.A., et al. Ranitidine interference with standard amphetamine immunoassay. Clin Chim Acta 438 (2015), 307–308.
36. 36 Manzi, S., Law, T., Shannon, M.W., Methylphenidate produces a false-positive urine amphetamine screen. Pediatr Emerg Care, 18(5), 2002, 401.
37. 37 Melanson, S.E., Lee-Lewandrowski, E., Griggs, D.A., Long, W.H., Flood, J.G., Reduced interference by phenothiazines in amphetamine drug of abuse immunoassays. Arch Pathol Lab Med 130:12 (2006), 1834–1838.
38. 38 Merigian, K.S., Browning, R., Kellerman, A., Doxepin causing false-positive urine test for amphetamine. Ann Emerg Med, 22(8), 1993, 1370.
39. 39 Merigian, K.S., Browning, R.G., Desipramine and amantadine causing false-positive urine test for amphetamine. Ann Emerg Med 22:12 (1993), 1927–1928.
40. 40 Nice, A., Maturen, A., False-positive urine amphetamine screen with ritodrine. Clin Chem 35:7 (1989), 1542–1543.
41. 41 Nixon, A.L., Long, W.H., Puopolo, P.R., Flood, J.G., Bupropion metabolites produce false-positive urine amphetamine results. Clin Chem 41:6, Pt 1 (1995), 955–956.
42. 42 Olsen, K.M., Gulliksen, M., Christophersen, A.S., Metabolites of chlorpromazine and brompheniramine may cause false-positive urine amphetamine results with monoclonal EMIT d.a.u. immunoassay. Clin Chem 38:4 (1992), 611–612.
43. 43 Poklis, A., Hall, K.V., Still, J., Binder, S.R., Ranitidine interference with the monoclonal EMIT d.a.u. amphetamine/methamphetamine immunoassay. J Anal Toxicol 15:2 (1991), 101–103.
44. 44 Poklis, A., Moore, K.A., Response of EMIT amphetamine immunoassays to urinary desoxyephedrine following Vicks inhaler use. Ther Drug Monit 17:1 (1995), 89–94.
45. 45 Roberge, R.J., Luellen, J.R., Reed, S., False-positive amphetamine screen following a trazodone overdose. J Toxicol Clin Toxicol 39:2 (2001), 181–182.
46. 46 Romberg, R.W., Needleman, S.B., Snyder, J.J., Greedan, A., Methamphetamine and amphetamine derived from the metabolism of selegiline. J Forensic Sci 40:6 (1995), 1100–1102.
47. 47 Stout, P.R., Klette, K.L., Horn, C.K., Evaluation of ephedrine, pseudoephedrine and phenylpropanolamine concentrations in human urine samples and a comparison of the specificity of DRI amphetamines and Abuscreen online (KIMS) amphetamines screening immunoassays. J Forensic Sci 49:1 (2004), 160–164.
48. 48 Vorce, S.P., Holler, J.M., Cawrse, B.M., Magluilo, J. Jr., Dimethylamylamine: a drug causing positive immunoassay results for amphetamines. J Anal Toxicol 35:3 (2011), 183–187.
49. 49 Weintraub, D., Linder, M.W., Amphetamine positive toxicology screen secondary to bupropion. Depress Anxiety 12:1 (2000), 53–54.
50. 50 Yee, L.M., Wu, D., False-positive amphetamine toxicology screen results in three pregnant women using labetalol. Obstet Gynecol 117:2, Pt 2 (2011), 503–506.
51. 51 Daypro [package insert], 2016, G. D. Searle LLC, Division of Pfizer Inc, New York, NY.
52. 52 Zoloft [package insert], 2014, Roerig, a division of Pfizer Inc, New York, NY.
53. 53 Blank, A., Hellstern, V., Schuster, D., et al. Efavirenz treatment and false-positive results in benzodiazepine screening tests. Clin Infect Dis 48:12 (2009), 1787–1789.
54. 54 Fraser, A.D., Meatherall, R., Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values. J Anal Toxicol 20:4 (1996), 217–223.
55. 55 Fraser, A.D., Meatherall, R., Improved cross-reactivity to alpha OH triazolam in the BMC CEDIA DAU urine benzodiazepine assay. Ther Drug Monit 20:3 (1998), 331–334.
56. 56 Lum, G., Mushlin, B., Farney, L., False-positive rates for the qualitative analysis of urine benzodiazepines and metabolites with the reformulated Abbott Multigent reagents. Clin Chem 54:1 (2008), 220–221.
57. 57 Meatherall, R., Fraser, A.D., Comparison of four immunoassays for the detection of lorazepam in urine. Ther Drug Monit 20:6 (1998), 673–675.
58. 58 Nasky, K.M., Cowan, G.L., Knittel, D.R., False-positive urine screening for benzodiazepines: an association with sertraline? A two-year retrospective chart analysis. Psychiatry (Edgmont) 6:7 (2009), 36–39.
59. 59 Roder, C.S., Heinrich, T., Gehrig, A.K., Mikus, G., Misleading results of screening for illicit drugs during efavirenz treatment. AIDS 21:10 (2007), 1390–1391.
60. 60 Marinol [Package insert], 2016, AbbVie Inc, Chicago, IL.
61. 61 Cesamet [Package insert], 2013, Meda Pharmaceuticals Inc, Somerset, NJ.
62. 62 Tests for drugs of abuse. Med Lett Drugs Ther 44:1137 (2002), 71–73.
63. 63 Cotten, S.W., Duncan, D.L., Burch, E.A., Seashore, C.J., Hammett-Stabler, C.A., Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay. Clin Biochem 45:9 (2012), 605–609.
64. 64 Felton, D., Zitomersky, N., Manzi, S., Lightdale, J.R., 13-year-old girl with recurrent, episodic, persistent vomiting: out of the pot and into the fire. Pediatrics 135:4 (2015), e1060–e1063.
65. 65 Fraser, A.D., Meatherall, R., Lack of interference by nabilone in the EMIT d.a.u. cannabinoid assay, Abbott TDx cannabinoid assay, and a sensitive TLC assay for delta 9-THC-carboxylic acid. J Anal Toxicol, 13(4), 1989, 240.
66. 66 la Porte, C.J., Droste, J.A., Burger, D.M., False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampin. Ther Drug Monit, 28(2), 2006, 286.
67. 67 Oosthuizen, N.M., Laurens, J.B., Efavirenz interference in urine screening immunoassays for tetrahydrocannabinol. Ann Clin Biochem 49:Pt 2 (2012), 194–196.
68. 68 Rollins, D.E., Jennison, T.A., Jones, G., Investigation of interference by nonsteroidal anti-inflammatory drugs in urine tests for abused drugs. Clin Chem 36:4 (1990), 602–606.
69. 69 Rossi, S., Yaksh, T., Bentley, H., van den Brande, G., Grant, I., Ellis, R., Characterization of interference with 6 commercial delta9-tetrahydrocannabinol immunoassays by efavirenz (glucuronide) in urine. Clin Chem 52:5 (2006), 896–897.
70. 70 Steinagle, G.C., Upfal, M., Concentration of marijuana metabolites in the urine after ingestion of hemp seed tea. J Occup Environ Med 41:6 (1999), 510–513.
71. 71 De Giorgio, F., Rossi, S.S., Rainio, J., Chiarotti, M., Cocaine found in a child's hair due to environmental exposure?. Int J Legal Med 118:5 (2004), 310–312.
72. 72 Hickey, K., Seliem, R., Shields, J., McKee, A., Nichols, J.H., A positive drug test in the pain management patient: deception or herbal cross-reactivity?. Clin Chem 48:6, Pt 1 (2002), 958–960.
73. 73 Mazor, S.S., Mycyk, M.B., Wills, B.K., Brace, L.D., Gussow, L., Erickson, T., Coca tea consumption causes positive urine cocaine assay. Eur J Emerg Med 13:6 (2006), 340–341.
74. 74 O'Neil, M.J., Smith, A., Heckelman, P.E., (eds.) The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 13th ed, 2001, Merck Research Laboratories, Whitehouse Station, NJ.
75. 75 Baden, L.R., Horowitz, G., Jacoby, H., Eliopoulos, G.M., Quinolones and false-positive urine screening for opiates by immunoassay technology. JAMA 286:24 (2001), 3115–3119.
76. 76 Cooreman, S., Deprez, C., Martens, F., Van Bocxlaer, J., Croes, K., A comprehensive LC-MS-based quantitative analysis of fentanyl-like drugs in plasma and urine. J Sep Sci 33:17-18 (2010), 2654–2662.
77. 77 Daher, R., Haidar, J.H., Al-Amin, H., Rifampin interference with opiate immunoassays. Clin Chem 48:1 (2002), 203–204.
78. 78 de Paula, M., Saiz, L.C., Gonzalez-Revalderia, J., Pascual, T., Alberola, C., Miravalles, E., Rifampicin causes false-positive immunoassay results for urine opiates. Clin Chem Lab Med 36:4 (1998), 241–243.
79. 79 Herrera, P., Ortiz, E., Tena, T., Lora, C., Presence of rifampicin in urine causes cross-reactivity with opiates using the KIMS method. J Anal Toxicol, 19(3), 1995, 200.
80. 80 Kronstrand, R., Selden, T.G., Josefsson, M., Analysis of buprenorphine, norbuprenorphine, and their glucuronides in urine by liquid chromatography-mass spectrometry. J Anal Toxicol 27:7 (2003), 464–470.
81. 81 Lichtenwalner, M.R., Mencken, T., Tully, R., Petosa, M., False-positive immunochemical screen for methadone attributable to metabolites of verapamil. Clin Chem 44:5 (1998), 1039–1041.
82. 82 Meatherall, R., Dai, J., False-positive EMIT II opiates from ofloxacin. Ther Drug Monit 19:1 (1997), 98–99.
83. 83 Rogers, S.C., Pruitt, C.W., Crouch, D.J., Caravati, E.M., Rapid urine drug screens: diphenhydramine and methadone cross-reactivity. Pediatr Emerg Care 26:9 (2010), 665–666.
84. 84 Straley, C.M., Cecil, E.J., Herriman, M.P., Gatifloxacin interference with opiate urine drug screen. Pharmacotherapy 26:3 (2006), 435–439.
85. 85 Struempler, R.E., Excretion of codeine and morphine following ingestion of poppy seeds. J Anal Toxicol 11:3 (1987), 97–99.
86. 86 Syed, H., Som, S., Khan, N., Faltas, W., Doxylamine toxicity: seizure, rhabdomyolysis and false positive urine drug screen for methadone. BMJ Case Rep, 2009, 2009, 10.1136/bcr.09.2008.0879 pii: bcr09.2008.0879. Epub 2009 Mar 17.
87. 87 van As, H., Stolk, L.M., Rifampicin cross-reacts with opiate immunoassay. J Anal Toxicol, 23(1), 1999, 71.
88. 88 Vincent, E.C., Zebelman, A., Goodwin, C., Stephens, M.M., Clinical inquiries: what common substances can cause false positives on urine screens for drugs of abuse?. J Fam Pract, 55(10), 2006 893-894, 897.
89. 89 Wang, G., Huynh, K., Barhate, R., et al. Development of a homogeneous immunoassay for the detection of fentanyl in urine. Forensic Sci Int 206:1-3 (2011), 127–131.
90. 90 Zebelman, A.M., Troyer, B.L., Randall, G.L., Batjer, J.D., Detection of morphine and codeine following consumption of poppy seeds. J Anal Toxicol 11:3 (1987), 131–132.
91. 91 Bond, G.R., Steele, P.E., Uges, D.R., Massive venlafaxine overdose resulted in a false positive Abbott AxSYM urine immunoassay for phencyclidine. J Toxicol Clin Toxicol 41:7 (2003), 999–1002.
92. 92 Geraci, M.J., Peele, J., McCoy, S.L., Elias, B., Phencyclidine false positive induced by lamotrigine (Lamictal(R)) on a rapid urine toxicology screen. Int J Emerg Med 3:4 (2010), 327–331.
93. 93 Gupta, R.C., Lu, I., Oei, G.L., Lundberg, G.D., Determination of phencyclidine (PCP) in urine and illicit street drug samples. Clin Toxicol 8:6 (1975), 611–621.
94. 94 Hull, M.J., Griggs, D., Knoepp, S.M., Smogorzewska, A., Nixon, A., Flood, J.G., Postmortem urine immunoassay showing false-positive phencyclidine reactivity in a case of fatal tramadol overdose. Am J Forensic Med Pathol 27:4 (2006), 359–362.
95. 95 Khajawall, A.M., Simpson, G.M., Critical interpretation of urinary phencyclidine monitoring. Adv Alcohol Subst Abuse 3:3 (1984), 65–73.
96. 96 Ly, B.T., Thornton, S.L., Buono, C., Stone, J.A., Wu, A.H., False-positive urine phencyclidine immunoassay screen result caused by interference by tramadol and its metabolites. Ann Emerg Med 59:6 (2012), 545–547.
97. 97 Penders, T.M., Gestring, R.E., Vilensky, D.A., Intoxication delirium following use of synthetic cathinone derivatives. Am J Drug Alcohol Abuse 38:6 (2012), 616–617.
98. 98 Rengarajan, A., Mullins, M.E., How often do false-positive phencyclidine urine screens occur with use of common medications?. Clin Toxicol (Phila) 51:6 (2013), 493–496.
99. 99 Sena, S.F., Kazimi, S., Wu, A.H., False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine. Clin Chem 48:4 (2002), 676–677.
100. 100 Shannon, M., Recent ketamine administration can produce a urine toxic screen which is falsely positive for phencyclidine. Pediatr Emerg Care, 14(2), 1998, 180.
101. 101 Al-Mateen, C.S., Wolf, C.E. II, Falsely elevated imipramine levels in a patient taking quetiapine. J Am Acad Child Adolesc Psychiatry 41:1 (2002), 5–6.
102. 102 Chattergoon, D.S., Verjee, Z., Anderson, M., et al. Carbamazepine interference with an immune assay for tricyclic antidepressants in plasma. J Toxicol Clin Toxicol 36:1-2 (1998), 109–113.
103. 103 Dasgupta, A., Wells, A., Datta, P., False-positive serum tricyclic antidepressant concentrations using fluorescence polarization immunoassay due to the presence of hydroxyzine and cetirizine. Ther Drug Monit 29:1 (2007), 134–139.
104. 104 Fleischman, A., Chiang, V.W., Carbamazepine overdose recognized by a tricyclic antidepressant assay. Pediatrics 107:1 (2001), 176–177.
105. 105 Matos, M.E., Burns, M.M., Shannon, M.W., False-positive tricyclic antidepressant drug screen results leading to the diagnosis of carbamazepine intoxication. Pediatrics, 105(5), 2000, E66.
106. 106 Schussler, J.M., Juenke, J.M., Schussler, I., Quetiapine and falsely elevated nortriptyline level. Am J Psychiatry, 160(3), 2003, 589.
107. 107 Sloan, K.L., Haver, V.M., Saxon, A.J., Quetiapine and false-positive urine drug testing for tricyclic antidepressants. Am J Psychiatry 157:1 (2000), 148–149.
108. 108 Sorisky, A., Watson, D.C., Positive diphenhydramine interference in the EMIT-st assay for tricyclic antidepressants in serum. Clin Chem, 32(4), 1986, 715.
109. 109 Van Hoey, N.M., Effect of cyclobenzaprine on tricyclic antidepressant assays. Ann Pharmacother 39:7-8 (2005), 1314–1317.
110. 110 Wians, F.H. Jr., Norton, J.T., Wirebaugh, S.R., False-positive serum tricyclic antidepressant screen with cyproheptadine. Clin Chem 39:6 (1993), 1355–1356.
111. 111 Yuan, C.M., Spandorfer, P.R., Miller, S.L., Henretig, F.M., Shaw, L.M., Evaluation of tricyclic antidepressant false positivity in a pediatric case of cyproheptadine (periactin) overdose. Ther Drug Monit 25:3 (2003), 299–304.
112. 112 DrugCheck® K2/Spice Test [package insert], 2012, Express Diagnostic Int'l Inc, Blue Earth, MN.
113. 113 Substance Abuse and Mental Health Services Administration, Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. 2014, Substance Abuse and Mental Health Services Administration;. HHS Publication (SMA), Rockville, MD, 14–4863 http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf Accessed October 12, 2016.
114. 114 National Institute on Drug Abuse, Marijuana. 2014, National Institute on Drug Abuse, Bethesda, MD NIH publication 15-3859 http://www.drugabuse.gov/sites/default/files/mjrrs_3.pdf Accessed October 12, 2016.
115. 115 28 legal medical marijuana states and DC: laws, fees, and possession limits. ProCon.org website http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881 Accessed November 18, 2016.
116. 116 State marijuana laws in 2016 map. Governing website http://www.governing.com/gov-data/state-marijuana-laws-map-medical-recreational.html Accessed November 19, 2016.
117. 117 Centers for Disease Control and Prevention, Inadvertent ingestion of marijuana—Los Angeles, California, 2009. MMWR Morb Mortal Wkly Rep 58:34 (2009), 947–950.
118. 118 Ellis, G.M. Jr., Mann, M.A., Judson, B.A., Schramm, N.T., Tashchian, A., Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 38:5 (1985), 572–578.
119. 119 Dackis, C.A., Pottash, A.L., Annitto, W., Gold, M.S., Persistence of urinary marijuana levels after supervised abstinence. Am J Psychiatry 139:9 (1982), 1196–1198.
120. 120 Hollister, L.E., Kanter, S.L., Laboratory verification of “heavy” and “light” users of cannabis. Drug Alcohol Depend 5:2 (1980), 151–152.
121. 121 Lowe, R.H., Abraham, T.T., Darwin, W.D., Herning, R., Cadet, J.L., Huestis, M.A., Extended urinary delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend 105:1-2 (2009), 24–32.
122. 122 Manno, J.E., Manno, B.R., Kemp, P.M., et al. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol 25:7 (2001), 538–549.
123. 123 Lacey, J., Brainard, K., Snitow, S., Drug Per Se Laws: A Review of Their Use in States. 2010, US Department of Transportation, National Highway Traffic Safety Administration, Washington, DC DOT HS 811 317 http://www.nhtsa.gov/staticfiles/nti/impaired_driving/pdf/811317.pdf Accessed October 12, 2016.
124. 124 Huestis, M.A., Henningfield, J.E., Cone, E.J., Blood cannabinoids, I: absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16:5 (1992), 276–282.
125. 125 Bergamaschi, M.M., Karschner, E.L., Goodwin, R.S., et al. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers’ blood on per se drugged driving laws. Clin Chem 59:3 (2013), 519–526.
126. 126 Levin, F.R., Mariani, J.J., Brooks, D.J., Xie, S., Murray, K.A., Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol. Drug Alcohol Depend 106:1 (2010), 65–68.
127. 127 Protonix Delayed-Release [package insert], 2014, Wyeth Pharmaceuticals Inc, a subsidiary of Pfizer Inc, Philadelphia, PA.
128. 128 Mulé, S.J., Lomax, P., Gross, S.J., Active and realistic passive marijuana exposure tested by three immunoassays and GC/MS in urine. J Anal Toxicol 12:3 (1988), 113–116.
129. 129 Perez-Reyes, M., Di Guiseppi, S., Mason, A.P., Davis, K.H., Passive inhalation of marihuana smoke and urinary excretion of cannabinoids. Clin Pharmacol Ther 34:1 (1983), 36–41.
130. 130 Cone, E.J., Johnson, R.E., Darwin, W.D., et al. Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol. J Anal Toxicol 11:3 (1987), 89–96.
131. 131 ElSohly, M.A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., Church, J.C., Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol Psychiatry 79:7 (2016), 613–619.
132. 132 ElSohly, M.A., Ross, S.A., Mehmedic, Z., Arafat, R., Yi, B., Banahan, B.F. III, Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci 45:1 (2000), 24–30.
133. 133 Cone, E.J., Bigelow, G.E., Herrmann, E.S., et al. Non-smoker exposure to secondhand cannabis smoke, I: urine screening and confirmation results. J Anal Toxicol 39:1 (2015), 1–12.
134. 134 Herrmann, E.S., Cone, E.J., Mitchell, J.M., et al. Non-smoker exposure to secondhand cannabis smoke, II: effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects. Drug Alcohol Depend 151 (2015), 194–202.
135. 135 Trescot, A.M., Datta, S., Lee, M., Hansen, H., Opioid pharmacology. Pain Physician 11:2 Suppl (2008), S133–S153.
136. 136 Peppin, J.F., Passik, S.D., Couto, J.E., et al. Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. Pain Med 13:7 (2012), 886–896.
137. 137 Drug Enforcement Administration, Department of Justice. Schedule of controlled substances: placement of tramadol into schedule IV: final rule. Fed Regist 79:127 (2014), 37623–37630 To be codified at 21 CFR Part 1308.14.
138. 138 Drug Enforcement Administration. Department of Justice. Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Fed Regist 79:163 (2014), 49661–49682 To be codified at 21 CFR Part 1308.
139. 139 Gourlay, D.L., Heit, H.A., Almahrezi, A., Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 6:2 (2005), 107–112.
140. 140 Passik, S.D., Kirsh, K.L., Whitcomb, L., et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther 26:4 (2004), 552–561.
141. 141 Smith, H.S., Opioid metabolism. Mayo Clin Proc 84:7 (2009), 613–624.
142. 142 Smith, M.L., Hughes, R.O., Levine, B., Dickerson, S., Darwin, W.D., Cone, E.J., Forensic drug testing for opiates, VI: urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometry. J Anal Toxicol 19:1 (1995), 18–26.
143. 143 Melanson, S.E., Snyder, M.L., Jarolim, P., Flood, J.G., A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse. J Anal Toxicol 36:3 (2012), 201–206.
144. 144 Paul, B.D., Shimomura, E.T., Smith, M.L., A practical approach to determine cutoff concentrations for opiate testing with simultaneous detection of codeine, morphine, and 6-acetylmorphine in urine. Clin Chem 45:4 (1999), 510–519.
145. 145 Keary, C.J., Wang, Y., Moran, J.R., Zayas, L.V., Stern, T.A., Toxicologic testing for opiates: understanding false-positive and false-negative test results. Prim Care Companion CNS Disord, 14(4), 2012, 10.4088/PCC.12f01371 pii: PCC.12f01371. Epub 2012 Jul 26.
146. 146 Cone, E.J., Heit, H.A., Caplan, Y.H., Gourlay, D., Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J Anal Toxicol 30:1 (2006), 1–5.
147. 147 Chen, Y.L., Hanson, G.D., Jiang, X., Naidong, W., Simultaneous determination of hydrocodone and hydromorphone in human plasma by liquid chromatography with tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 769:1 (2002), 55–64.
148. 148 Oyler, J.M., Cone, E.J., Joseph, R.E. Jr., Huestis, M.A., Identification of hydrocodone in human urine following controlled codeine administration. J Anal Toxicol 24:7 (2000), 530–535.
149. 149 Cone, E.J., Dickerson, S., Paul, B.D., Mitchell, J.M., Forensic drug testing for opiates, V: urine testing for heroin, morphine, and codeine with commercial opiate immunoassays. J Anal Toxicol 17:3 (1993), 156–164.
150. 150 Critical issues in urinalysis of abused substances: report of the Substance-Abuse Testing Committee. Clin Chem 34:3 (1988), 605–632.
151. 151 Cone, E.J., Fant, R.V., Rohay, J.M., et al. Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol 27:2 (2003), 57–67 discussion 67.
152. 152 Samer, C.F., Daali, Y., Wagner, M., et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 160:4 (2010), 919–930.
153. 153 Yee, D.A., Best, B.M., Atayee, R.S., Pesce, A.J., Observations on the urine metabolic ratio of oxymorphone to oxycodone in pain patients. J Anal Toxicol 36:4 (2012), 232–238.
154. 154 White, R.M., Black, M.L., Pain Management Testing Reference. 2007, AAAC Press, Washington, DC.
155. 155 Chang, K.C., Huang, C.L., Liang, H.Y., et al. Gender-specific differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence. J Cardiovasc Electrophysiol 23:5 (2012), 527–533.
156. 156 Shaiova, L., Berger, A., Blinderman, C.D., et al. Consensus guideline on parenteral methadone use in pain and palliative care. Palliat Support Care 6:2 (2008), 165–176.
157. 157 Galloway, F.R., Bellet, N.F., Methadone conversion to EDDP during GC-MS analysis of urine samples. J Anal Toxicol 23:7 (1999), 615–619.
158. 158 Methadone/EDDP homogeneous enzyme immunoassay (HEIA™), Immunolysis Corporation website. http://immunalysis.com/wp-content/uploads/2014/05/06_MKT-1002-Methadone-EDDP-Factsheet-Ver.-B-Final.pdf Accessed October 16, 2016.
159. 159 Alonso-Zaldivar, R., FDA renews warning for powerful painkiller patch—the agency says the drug has been misused and wrongly prescribed. Los Angeles Times, 2007 http://articles.latimes.com/2007/dec/22/nation/na-patch22 Accessed October 16, 2016.
160. 160 US Food and Drug Administration, Information for Healthcare Professionals: Fentanyl Transdermal System. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm125844.htm Published July 15, 2015. Accessed October 16, 2016.
161. 161 Cole, J.M., Best, B.M., Pesce, A.J., Variability of transdermal fentanyl metabolism and excretion in pain patients. J Opioid Manag 6:1 (2010), 29–39.
162. 162 Grond, S., Sablotzki, A., Clinical pharmacology of tramadol. Clin Pharmacokinet 43:13 (2004), 879–923.
163. 163 El-Sayed, A.A., Mohamed, K.M., Nasser, A.Y., Button, J., Holt, D.W., Simultaneous determination of tramadol, O-desmethyltramadol and N-desmethyltramadol in human urine by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 926 (2013), 9–15.
164. 164 Perry, P.J., Alexander, B., Liskow, B.I., DeVane, C.L., Psychotropic Drug Handbook. 8th ed., 2007, Lippincott Williams & Wilkins, Baltimore, MD.
165. 165 Jann, M., Kennedy, W.K., Lopez, G., Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Pract 27:1 (2014), 5–16.
166. 166 elSohly, M.A., Feng, S., Salamone, S.J., Wu, R., A sensitive GC-MS procedure for the analysis of flunitrazepam and its metabolites in urine. J Anal Toxicol 21:5 (1997), 335–340.
167. 167 Lee, D.C., Sedative-hypnotics. Hoffman, R.S., Howland, M., Lewin, N.A., Nelson, L.S., Goldfrank, L.R., (eds.) Goldfrank's Toxicologic Emergencies, 10e, 2015, McGraw-Hill, New York, NY http://accesspharmacy.mhmedical.com/book.aspx?bookid=1163 Accessed October 16, 2016.
168. 168 Trevor, A.J., Sedative-hypnotic drugs. Katzung, B.G., Trevor, A.J., (eds.) Basic & Clinical Pharmacology, 13e, 2015, McGraw-Hill, New York, NY http://accesspharmacy.mhmedical.com/content.aspx?bookid=1193&Sectionid=69106765 Accessed October 19, 2016.
169. 169 Meatherall, R., Benzodiazepine screening using EMIT II and TDx: urine hydrolysis pretreatment required. J Anal Toxicol 18:7 (1994), 385–390.
170. 170 Meatherall, R., Optimal enzymatic hydrolysis of urinary benzodiazepine conjugates. J Anal Toxicol 18:7 (1994), 382–384.
171. 171 Meatherall, R.C., Fraser, A.D., CEDIA dau Benzodiazepine screening assay: a reformulation. J Anal Toxicol 22:4 (1998), 270–273.
172. 172 West, R., Pesce, A., West, C., et al. Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population. Pain Physician 13:1 (2010), 71–78.
173. 173 Eskridge, K.D., Guthrie, S.K., Clinical issues associated with urine testing of substances of abuse. Pharmacotherapy 17:3 (1997), 497–510.
174. 174 Kronstrand, R., Andersson, M.C., Ahlner, J., Larson, G., Incorporation of selegiline metabolites into hair after oral selegiline intake. J Anal Toxicol 25:7 (2001), 594–601.
175. 175 Smith, M.L., Nichols, D.C., Underwood, P., et al. Methamphetamine and amphetamine isomer concentrations in human urine following controlled Vicks VapoInhaler administration. J Anal Toxicol 38:8 (2014), 524–527.
176. 176 Schaeffer, T., Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics. J Med Toxicol 8:4 (2012), 400–407.
177. 177 Cohen, P.A., A false sense of security? The U.S. Food and Drug Administration's framework for evaluating new supplement ingredients. Antioxid Redox Signal 16:5 (2012), 458–460.
178. 178 Eliason, M.J., Eichner, A., Cancio, A., Bestervelt, L., Adams, B.D., Deuster, P.A., Case reports: death of active duty soldiers following ingestion of dietary supplements containing 1,3-dimethylamylamine (DMAA). Mil Med 177:12 (2012), 1455–1459.
179. 179 Gee, P., Tallon, C., Long, N., Moore, G., Boet, R., Jackson, S., Use of recreational drug 1,3 dimethylamylamine (DMAA) [corrected] associated with cerebral hemorrhage. Ann Emerg Med 60:4 (2012), 431–434.
180. 180 Goldstein, R.A., DesLauriers, C., Burda, A., Johnson-Arbor, K., Cocaine: history, social implications, and toxicity: a review. Semin Diagn Pathol 26:1 (2009), 10–17.
181. 181 Rapuri, S.B., Ramaswamy, S., Madaan, V., Rasimas, J.J., Krahn, L.E., ‘Weed'out false-positive urine drug screens: table of possible false positives. Current Psychiatry 5:8 (2006), 107–110.
182. 182 Reisfield, G.M., Haddad, J., Wilson, G.R., et al. Failure of amoxicillin to produce false-positive urine screens for cocaine metabolite. J Anal Toxicol 32:4 (2008), 315–318.
183. 183 Jacobson, D.M., Berg, R., Grinstead, G.F., Kruse, J.R., Duration of positive urine for cocaine metabolite after ophthalmic administration: implications for testing patients with suspected Horner syndrome using ophthalmic cocaine. Am J Ophthalmol 131:6 (2001), 742–747.
184. 184 Dasgupta, A., Beating Drug Tests and Defending Positive Results: A Toxicologist's Perspective. 2010, Humana Press, New York, NY.
185. 185 Substance Abuse and Mental Health Services Administration, The DAWN Report: Emergency Department Visits Involving Phencyclidine (PCP). 2014, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, Rockville, MD http://www.samhsa.gov/data/sites/default/files/DAWN143/DAWN143/sr143-emergency-phencyclidine-2013.pdf Accessed October 12, 2016.
186. 186 Modesto-Lowe, V., Petry, N.M., Recognizing and managing “illy” intoxication. Psychiatr Serv, 52(12), 2001, 1660.
187. 187 Peters, R.J. Jr., Williams, M., Ross, M.W., Atkinson, J., McCurdy, S.A., The use of fry (embalming fluid and PCP-laced cigarettes or marijuana sticks) among crack cocaine smokers. J Drug Educ 38:3 (2008), 285–295.
188. 188 Peters, R.J. Jr., Kelder, S.H., Meshack, A., Yacoubian, G.S. Jr., McCrimmons, D., Ellis, A., Beliefs and social norms about cigarettes or marijuana sticks laced with embalming fluid and phencyclidine (PCP): why youth use “Fry”. Subst Use Misuse 40:4 (2005), 563–571.
189. 189 Olmedo, R.E., Phencyclidine and ketamine. Hoffman, R.S., Howland, M., Lewin, N.A., Nelson, L.S., Goldfrank, L.R., (eds.) Goldfrank's Toxicologic Emergencies, 10e, 2015, McGraw-Hill, New York, NY http://accesspharmacy.mhmedical.com/book.aspx?bookid=1163 Accessed October 16, 2016.
190. 190 Weiner, A.L., Vieira, L., McKay, C.A., Bayer, M.J., Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 18:4 (2000), 447–451.
191. 191 Andrade, C., Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression. J Clin Psychiatry 76:5 (2015), 628–631.
192. 192 Fanta, S., Kinnunen, M., Backman, J.T., Kalso, E., Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol 71:4 (2015), 441–447.
193. 193 Nguyen, L., Marshalek, P.J., Weaver, C.B., Cramer, K.J., Pollard, S.E., Matsumoto, R.R., Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review. Neuropsychiatr Dis Treat 11 (2015), 2667–2673.
194. 194 Macher, A.M., Penders, T.M., False-positive phencyclidine immunoassay results caused by 3,4-methylenedioxypyrovalerone (MDPV). Drug Test Anal 5:2 (2013), 130–132.
195. 195 Substance Abuse and Mental Health Services Administration, Spice, bath salts, and behavioral health. Advisory, 13, 2014 Substance Abuse and Mental Health Services Administration website http://store.samhsa.gov/shin/content/SMA14-4858/SMA14-4858.pdf Accessed October 16, 2016.
196. 196 Baumann, M.H., Partilla, J.S., Lehner, K.R., Psychoactive “bath salts”: not so soothing. Eur J Pharmacol 698:1-3 (2013), 1–5.
197. 197 Cameron, K., Kolanos, R., Vekariya, R., De Felice, L., Glennon, R.A., Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of “bath salts,” produce opposite effects at the human dopamine transporter. Psychopharmacology (Berl) 227:3 (2013), 493–499.
198. 198 Prosser, J.M., Nelson, L.S., The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:1 (2012), 33–42.
199. 199 Wyman, J.F., Lavins, E.S., Engelhart, D., et al. Postmortem tissue distribution of MDPV following lethal intoxication by “bath salts”. J Anal Toxicol 37:3 (2013), 182–185.
200. 200 Office of National Drug Control Policy, Fact Sheet: Synthetic Drugs. 2012, Office of National Drug Control Policy, Executive Office of the President, Washington, DC https://www.whitehouse.gov/sites/default/files/ondcp/Fact_Sheets/synthetic_drugs_fact_sheet_12-6-12.pdf Accessed November 16, 2016.
201. 201 McGraw, M.M., Is your patient high on “bath salts”?. Nursing 42:1 (2012), 26–32 quiz 32-33.
202. 202 Adamowicz, P., Gil, D., Skulska, A., Tokarczyk, B., Analysis of MDPV in blood–determination and interpretation. J Anal Toxicol 37:5 (2013), 308–312.
203. 203 Pearson, J.M., Hargraves, T.L., Hair, L.S., et al. Three fatal intoxications due to methylone. J Anal Toxicol 36:6 (2012), 444–451.
204. 204 Namera, A., Konuma, K., Kawamura, M., et al. Time-course profile of urinary excretion of intravenously administered alpha-pyrrolidinovalerophenone and alpha-pyrrolidinobutiophenone in a human. Forensic Toxicol 32:1 (2014), 68–74.
205. 205 Ellefsen, K.N., Anizan, S., Castaneto, M.S., et al. Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology. Drug Test Anal 6:7-8 (2014), 728–738.
206. 206 Swortwood, M.J., Boland, D.M., DeCaprio, A.P., Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis. Anal Bioanal Chem 405:4 (2013), 1383–1397.
207. 207 Atwood, B.K., Huffman, J., Straiker, A., Mackie, K., JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160:3 (2010), 585–593.
208. 208 Huffman, J.W., Zengin, G., Wu, M.J., et al. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents: new highly selective CB(2) receptor agonists. Bioorg Med Chem 13:1 (2005), 89–112.
209. 209 Wohlfarth, A., Scheidweiler, K.B., Castaneto, M., et al. Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens. Clin Chem Lab Med 53:3 (2015), 423–434.
210. 210 Castaneto, M.S., Gorelick, D.A., Desrosiers, N.A., Hartman, R.L., Pirard, S., Huestis, M.A., Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144 (2014), 12–41.
211. 211 Favretto, D., Pascali, J.P., Tagliaro, F., New challenges and innovation in forensic toxicology: focus on the “New Psychoactive Substances”. J Chromatogr A 1287 (2013), 84–95.
212. 212 Wells, D.L., Ott, C.A., The “new” marijuana. Ann Pharmacother 45:3 (2011), 414–417.
213. 213 Johnston, L.D., O'Malley, P.M., Miech, R.A., Bachman, J.G., Schulenberg, J.E., Monitoring the Future: National Survey Results on Drug Use, 1975-2015: Overview, Key Findings on Adolescent Drug Use. 2016, Institute for Social Research, the University of Michigan, Ann Arbor, MI http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2015.pdf Accessed October 12, 2016.
214. 214 Spaderna, M., Addy, P.H., D'Souza, D.C., Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl) 228:4 (2013), 525–540.
215. 215 Synthetic Drug Abuse Prevention Act of 2012, 21 USC §§801 note, 811, 812, 2012.
216. 216 Sacco, L.N., Finklea, K., Synthetic drugs: overview and issues for Congress*. J Drug Addict Educ Erad 8:4 (2012), 197–211.
217. 217 Barnes, A.J., Spinelli, E., Young, S., Martin, T.M., Kleete, K.L., Huestis, M.A., Validation of an ELISA synthetic cannabinoids urine assay. Ther Drug Monit 37:5 (2015), 661–669.
218. 218 Walker, J.B., Sytsma, K.J., Treutlein, J., Wink, M., Salvia (Lamiaceae) is not monophyletic: implications for the systematics, radiation, and ecological specializations of Salvia and tribe Mentheae. Am J Bot 91:7 (2004), 1115–1125.
219. 219 Rech, M.A., Donahey, E., Cappiello Dziedzic, J.M., Oh, L., Greenhalgh, E., New drugs of abuse. Pharmacotherapy 35:2 (2015), 189–197.
220. 220 McDonough, P.C., Holler, J.M., Vorce, S.P., Bosy, T.Z., Magluilo, J. Jr., Past, M.R., The detection and quantitative analysis of the psychoactive component of Salvia divinorum, salvinorin A, in human biological fluids using liquid chromatography-mass spectrometry. J Anal Toxicol 32:6 (2008), 417–421.
221. 221 Leickly, E., McDonell, M.G., Vilardaga, R., et al. High levels of agreement between clinic-based ethyl glucuronide (EtG) immunoassays and laboratory-based mass spectrometry. Am J Drug Alcohol Abuse 41:3 (2015), 246–250.
222. 222 Reisfield, G.M., Goldberger, B.A., Pesce, A.J., et al. Ethyl glucuronide, ethyl sulfate, and ethanol in urine after intensive exposure to high ethanol content mouthwash. J Anal Toxicol 35:5 (2011), 264–268.
223. 223 Linder, M.W., Keck, P.E. Jr., Standards of laboratory practice: antidepressant drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 44:5 (1998), 1073–1084.
224. 224 Petit, J.M., Spiker, D.G., Ruwitch, J.F., Ziegler, V.E., Weiss, A.N., Biggs, J.T., Tricyclic antidepressant plasma levels and adverse effects after overdose. Clin Pharmacol Ther 21:1 (1977), 47–51.
225. 225 Melanson, S.E., Lewandrowski, E.L., Griggs, D.A., Flood, J.G., Interpreting tricyclic antidepressant measurements in urine in an emergency department setting: comparison of two qualitative point-of-care urine tricyclic antidepressant drug immunoassays with quantitative serum chromatographic analysis. J Anal Toxicol 31:5 (2007), 270–275.
226. 226 Baselt, R.C., Disposition of Toxic Drugs and Chemicals in Man. 5th ed., 2000, Chemical Toxicology Institute, Foster City, CA.